Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.78 |
| ▸ | PGR | P06401 | 5/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.78 |
| ▸ | DRD2 | P14416 | 1/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.68 |
| ▸ | MMP1 | P03956 | 5/20 | 0.68 |
| ▸ | USP2 | O75604 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | MLNR | O43193 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625619 | 1.00 | NR3C1 (0.78) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL4625624 | 1.00 | NR3C1 (0.78) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL9160605 | 0.97 | NR3C1 (0.83) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL11431304 | 0.91 | NR3C1 (0.78) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL11436665 | 0.90 | NR3C1 (0.80) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL11581106 | 0.90 | NR3C1 (0.80) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL11581104 | 0.90 | NR3C1 (0.80) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL4624240 | 0.89 | NR3C1 (0.80) | NR3C1PGRNR1I2MAPTCYP3A4 | |
| SCHEMBL4624245 | 0.89 | NR3C1 (0.80) | NR3C1PGRNR1I2MAPTCYP3A4 | |
| SCHEMBL4624243 | 0.89 | NR3C1 (0.80) | NR3C1PGRNR1I2MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563731-B2 | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2013-10-22 | — | — | US | claimed |
| EP-1344526-B1 | PREVENTIVES/REMEDIES FOR INFLAMMATORY AIRWAY DISEASES | NIPPON SHINYAKU CO LTD (JP) | 2008-05-28 | — | — | EP | claimed |
| US-7214672-B2 | Preventives/remedies for inflammatory airway diseases | NIPPON SHINYAKU CO., LTD. (JP) | 2007-05-08 | — | — | US | claimed |
| US-20040053904-A1 | Preventive/ermedies for inflammatory airway diseases | NIPPON SHINYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | claimed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230019058-A1 | METHOD FOR THE TREATMENT OF VIRAL INFECTIONS | SOFTHALE NV (BE) | 2023-01-19 | — | — | US | disclosed |
| EP-3925607-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3424534-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10980746-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-20 | — | — | US | disclosed |
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| US-7214672-B2 | Preventives/remedies for inflammatory airway diseases | NIPPON SHINYAKU CO., LTD. (JP) | 2007-05-08 | — | — | US | disclosed |
| US-20050163724-A1 | Powdery respiratory tonic composition | SSP CO., LTD. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1514549-A1 | POWDERY RESPIRATORY TONIC COMPOSITION | SSP Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040053904-A1 | Preventive/ermedies for inflammatory airway diseases | NIPPON SHINYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | ADORA1, P2RY1, P2RY11 | NR3C1 1101/4885PGR 361/4885NR1I2 103/4885 |
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | NR3C1 1429/4885PGR 4115/4885NR1I2 867/4885 |
| US-10980746-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | NR3C1 3676/4885PGR 3750/4885NR1I2 3051/4885 |
| US-20040053904-A1 | Preventive/ermedies for inflammatory airway diseases | NR3C1, OXER1, NR5A1 | NR3C1 1/4885PGR 1911/4885NR1I2 249/4885 |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, SULT2A1 | NR3C1 76/4885PGR 723/4885NR1I2 208/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | NR3C1 2120/4885PGR 2596/4885NR1I2 767/4885 |
| US-20230019058-A1 | METHOD FOR THE TREATMENT OF VIRAL INFECTIONS | IL5, TSLP, CRH | NR3C1 11/4885PGR 2218/4885NR1I2 1124/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | NR3C1 3676/4885PGR 3750/4885NR1I2 3051/4885 |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, CCR1 | NR3C1 100/4885PGR 805/4885NR1I2 218/4885 |
| US-20050163724-A1 | Powdery respiratory tonic composition | IL5, IL17A, RORC | NR3C1 12/4885PGR 1432/4885NR1I2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.